249 related articles for article (PubMed ID: 24091025)
1. Antifungal resistance does not necessarily affect Candida glabrata fitness.
Borghi E; Andreoni S; Cirasola D; Ricucci V; Sciota R; Morace G
J Chemother; 2014 Feb; 26(1):32-6. PubMed ID: 24091025
[TBL] [Abstract][Full Text] [Related]
2. Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.
Klotz U; Schmidt D; Willinger B; Steinmann E; Buer J; Rath PM; Steinmann J
Mycoses; 2016 May; 59(5):312-8. PubMed ID: 26806376
[TBL] [Abstract][Full Text] [Related]
3. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Cleary JD; Garcia-Effron G; Chapman SW; Perlin DS
Antimicrob Agents Chemother; 2008 Jun; 52(6):2263-5. PubMed ID: 18378714
[TBL] [Abstract][Full Text] [Related]
4. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
[TBL] [Abstract][Full Text] [Related]
5. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
6. Absence of Azole or Echinocandin Resistance in Candida glabrata Isolates in India despite Background Prevalence of Strains with Defects in the DNA Mismatch Repair Pathway.
Singh A; Healey KR; Yadav P; Upadhyaya G; Sachdeva N; Sarma S; Kumar A; Tarai B; Perlin DS; Chowdhary A
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610199
[No Abstract] [Full Text] [Related]
7. Phenotypic and Molecular Evaluation of Echinocandin Susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis Strains Isolated during 30 Years in Argentina.
Morales-López S; Dudiuk C; Vivot W; Szusz W; Córdoba SB; Garcia-Effron G
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461313
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous Mutational Frequency and
Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
[TBL] [Abstract][Full Text] [Related]
9. Rapid Detection of FKS-Associated Echinocandin Resistance in Candida glabrata.
Zhao Y; Nagasaki Y; Kordalewska M; Press EG; Shields RK; Nguyen MH; Clancy CJ; Perlin DS
Antimicrob Agents Chemother; 2016 Nov; 60(11):6573-6577. PubMed ID: 27550360
[TBL] [Abstract][Full Text] [Related]
10. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
[TBL] [Abstract][Full Text] [Related]
12. The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination.
Healey KR; Nagasaki Y; Zimmerman M; Kordalewska M; Park S; Zhao Y; Perlin DS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971865
[No Abstract] [Full Text] [Related]
13. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Thompson GR; Wiederhold NP; Vallor AC; Villareal NC; Lewis JS; Patterson TF
Antimicrob Agents Chemother; 2008 Oct; 52(10):3783-5. PubMed ID: 18676885
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
15. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.
Shin JH; Chae MJ; Song JW; Jung SI; Cho D; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
J Clin Microbiol; 2007 Aug; 45(8):2385-91. PubMed ID: 17581937
[TBL] [Abstract][Full Text] [Related]
16. Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata.
Hu C; Fong G; Wurster S; Kontoyiannis DP; Beyda ND
Microbiol Spectr; 2022 Feb; 10(1):e0183721. PubMed ID: 35107318
[TBL] [Abstract][Full Text] [Related]
17. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong
Schell WA; Jones AM; Garvey EP; Hoekstra WJ; Schotzinger RJ; Alexander BD
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956419
[TBL] [Abstract][Full Text] [Related]
18.
Jiménez-Ortigosa C; Perez WB; Angulo D; Borroto-Esoda K; Perlin DS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630180
[TBL] [Abstract][Full Text] [Related]
19. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
Shields RK; Nguyen MH; Press EG; Cumbie R; Driscoll E; Pasculle AW; Clancy CJ
Antimicrob Agents Chemother; 2015 Dec; 59(12):7465-70. PubMed ID: 26392494
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species.
Astvad KM; Perlin DS; Johansen HK; Jensen RH; Arendrup MC
Antimicrob Agents Chemother; 2013 Jan; 57(1):177-82. PubMed ID: 23089746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
